Login
$XERS
$16.49 -$0.21 (1.26%) After hours

$XERS SEC Filings

Filed On Filing
06 Nov 2026 Form 4: McCulloch Kevin, See Remarks

Sold 25,000 shares ($312K)

05 Nov 2026 144
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Recorlev net revenue increased 93% year-over-year to more than $71 million

04 Nov 2026 Form 4: Pieper Steven, See Remarks

Sold 5,000 shares ($51.2K)

04 Nov 2026 Form 4: Hecht Beth, See Remarks

Sold 25,000 shares ($256K)

04 Nov 2026 Form 4: McCulloch Kevin, See Remarks

Sold 15,000 shares ($153K)

04 Nov 2026 Form 4: Taddese Menassie, Director

Received 22,365 shares as a grant or award · Disposed of 31,499 Stock Option (Right to Buy) (Grant/Award Acquisition) ($320K)

04 Nov 2026 Form 3: Taddese Menassie, Director

No securities owned

02 Nov 2026 144
02 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Experienced biopharmaceutical executive brings global commercial leadership, financial expertise, and public company governance experience

30 Oct 2026 SCHEDULE 13G/A
14 Oct 2026 8-K: Other Events

On October 13, 2026, Xeris Biopharma Holdings, Inc. (the “Company”), through its wholly owned subsidiary, Xeris Pharmaceuticals, Inc., filed patent infringement lawsuits in the United States District Court for the District of New Jersey ...

02 Oct 2026 Form 4: Pieper Steven, See Remarks

Sold 5,000 shares ($47K)

02 Oct 2026 Form 4: McCulloch Kevin, See Remarks

Sold 15,000 shares ($141K)

02 Oct 2026 Form 4: Hecht Beth, See Remarks

Sold 16,666 shares ($157K)

01 Oct 2026 144
29 Sep 2026 Form 4: McCulloch Kevin, See Remarks

Sold 25,000 shares ($250K)

28 Sep 2026 144
09 Sep 2026 8-K: Regulation FD Disclosure

Copyright © 2021-2026 Xeris Pharmaceuticals, Inc. All rights reserved. Today’s Agenda 2 1 Welcome & Introductions Allison Wey — SVP, Investor Relations 2 Becoming the Next Great Biopharmaceutical Company John Shannon – Chairman and Chief...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support